Abstract
Lymphoblastic lymphoma (LBL) was first described by Barcos and Lukes [] in 1975 and was termed convoluted T-cell lymphoma. Nathwani and colleagues [] in 1976 redefined LBL as a disease having discreet pathologic and clinical features from diffuse, small cleaved cell lymphoma. In 1982, the National Cancer Institute sponsored study of 1175 adult patients [] gave rise to the international Working Formulation of non-Hodgkin’s lymphomas, which recognized LBL as one of its 10 discreet clinical entities. Approximately 4% of patients in the above study were classified as having this high grade lymphoma. As the incidence of non-Hodgkin’s lymphomas in the United States is about 1:10,000 persons annually [], roughly 1200 individuals would be expected to be diagnosed with LBL in the United States each year. Despite the rarity of this condition, an understanding of the clinical, pathologic, and therapeutic principles used in the management of LBL is important, not only for LBL patients, but also for those with related disorders, such as other intermediate and high grade non-Hodgkin’s lymphomas and Tcell acute lymphoblastic leukemia (T-ALL).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
